{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:59:42Z","timestamp":1793401182268,"version":"4.5.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:sec id=\"ab-eoi250016-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Aflibercept, 8 mg, is an anti\u2013vascular endothelial growth factor (VEGF) formulation for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). While clinical trials report a comparable safety profile as aflibercept, 2 mg, clinical practice setting (so-called real-world) data on the incidence of intraocular inflammation (IOI) should be of value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250016-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the clinical practice setting incidence of IOI after intravitreal injection of aflibercept, 8 mg, for nAMD and DME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250016-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective case series involved a review of medical records at a single tertiary care center. Participants were all patients who received an intravitreal injection of aflibercept, 8 mg, for nAMD or DME from March 2024 to October 2024. Patients had received injections with other VEGF inhibitors before. Standard care included slitlamp examination before each injection and follow-up examination within 4 days after every injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250016-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>IOI adverse events (AEs) after injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250016-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Incidence of IOI after intravitreal injection of aflibercept, 8 mg. Secondary outcomes included the time point of IOI and best-corrected visual acuity (BCVA) during and after recovery of IOI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250016-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-one patients were treated with intravitreal aflibercept, 8 mg, injections: 23 with nAMD (56%) and 18 with DME (44%). Twenty-seven patients (66%) were male and 14 patients female (34%). A total of 136 intravitreal injections of aflibercept, 8 mg, were administered during the observation period. Five patients of 41 developed mild sterile IOI within 1 to 3 days after the intervention (incidence per injection, 3.7%; 95% CI, 1.6%-8.3%; incidence per patient, 12%; 95% CI, 5.3%-25.5%). Four patients had prior exposure to aflibercept, 8 mg, before the inflammation occurred; only 1 patient developed inflammation after the first dose. All patients were treated with local anti-inflammatory therapy (topical or subconjunctival corticosteroids), and 2 patients received additional systemic oral corticosteroids. No reduction of BCVA was observed after IOI-associated AEs receded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi250016-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This analysis in a clinical practice setting revealed a more frequent occurrence of IOI-associated AEs compared with previous clinical trials. All observed cases showed a mild IOI, which resolved under anti-inflammatory therapy without loss of BCVA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2025.0969","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:30:59Z","timestamp":1746099059000},"page":"499","source":"Crossref","is-referenced-by-count":28,"title":["Noninfectious Intraocular Inflammation After Intravitreal Aflibercept"],"prefix":"10.1001","volume":"143","author":[{"given":"Karoline E.","family":"Binder","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, TUM University Hospital, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Bleidi\u00dfel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, TUM University Hospital, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Charbel Issa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, TUM University Hospital, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Maier","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, TUM University Hospital, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard M.","family":"Coulibaly","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, TUM University Hospital, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"eoi250016r1","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases.","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"eoi250016r2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ophtha.2012.07.038","article-title":"Vascular endothelial growth factor A in intraocular vascular disease.","volume":"120","author":"Miller","year":"2013","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi250016r3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/aes.2016.12.03","article-title":"The use of aflibercept in ophthalmology: a review of randomized controlled trials.","volume":"2","author":"Chen","year":"2017","journal-title":"Ann Eye Sci"},{"issue":"1","key":"eoi250016r4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s12325-019-01147-6","article-title":"Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies.","volume":"37","author":"Carrasco","year":"2020","journal-title":"Adv Ther"},{"issue":"10432","key":"eoi250016r5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"issue":"10432","key":"eoi250016r6","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial.","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"eoi250016r7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial.","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"eoi250016r8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"issue":"2","key":"eoi250016r9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3109\/09286586.2015.1122067","article-title":"Intraocular inflammation following intravitreal injection of anti-VEGF medications for neovascular age-related macular degeneration.","volume":"23","author":"Knickelbein","year":"2016","journal-title":"Ophthalmic Epidemiol"},{"issue":"1","key":"eoi250016r10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajo.2015.04.013","article-title":"Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome.","volume":"160","author":"Dossarps","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"eoi250016r11","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1080\/09273948.2024.2361834","article-title":"Intra-ocular inflammation and occlusive retinal vasculitis following intravitreal injections of faricimab: a case report.","volume":"32","author":"Chen","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"eoi250016r12","article-title":"Acute intra ocular inflammation following intravitreal injections of faricimab: a multicentric case series.","author":"Le","year":"2024","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"eoi250016r13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamaophthalmol.2024.5889","article-title":"Inflammation and occlusive retinal vasculitis post faricimab.","volume":"143","author":"Bruening","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi250016r14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaophthalmol.2024.0530","article-title":"Severe intraocular inflammation following intravitreal faricimab.","volume":"142","author":"Thangamathesvaran","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"eoi250016r15","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004394","article-title":"Intraocular inflammation (IOI) associated with faricimab therapy: one-year real world outcomes.","author":"Montesel","year":"2025","journal-title":"Retina"},{"issue":"12","key":"eoi250016r16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.75937","article-title":"Intraocular inflammation following intravitreal faricimab injection in neovascular age-related macular degeneration.","volume":"16","author":"Parakh","year":"2024","journal-title":"Cureus"},{"key":"eoi250016r17","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-06736-6","article-title":"Vitritis following intravitreal faricimab: a retrospective monocentric analysis.","author":"Bourdin","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"eoi250016r18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajo.2024.08.008","article-title":"Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients.","volume":"269","author":"Ben Ghezala","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"eoi250016r19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","article-title":"Sterile intraocular inflammation associated with faricimab.","volume":"142","author":"Cozzi","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"eoi250016r20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","article-title":"Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration.","volume":"68","author":"Matsumoto","year":"2024","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"eoi250016r21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12886-024-03827-6","article-title":"Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report.","volume":"25","author":"Hashiya","year":"2025","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"eoi250016r22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12886-024-03788-w","article-title":"Aflibercept high-dose (8mg) related intraocular inflammation (IOI): a case series.","volume":"24","author":"Hoffmann","year":"2024","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"eoi250016r23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2010.08.047","article-title":"Appropriate use and reporting of uncontrolled case series in the medical literature.","volume":"151","author":"Kempen","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi250016r24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4274\/tjo.galenos.2020.84042","article-title":"Non-infectious intraocular inflammation following intravitreal anti-vascular endothelial growth factor injection.","volume":"51","author":"Kaya","year":"2021","journal-title":"Turk J Ophthalmol"},{"issue":"4","key":"eoi250016r25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaophthalmol.2014.5650","article-title":"Postmarketing analysis of aflibercept-related sterile intraocular inflammation.","volume":"133","author":"Hahn","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"eoi250016r26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ajo.2014.06.019","article-title":"Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes.","volume":"158","author":"Goldberg","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"eoi250016r27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.oret.2019.04.006","article-title":"Aflibercept-related sterile intraocular inflammation outcomes.","volume":"3","author":"Greenberg","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"eoi250016r28","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/IAE.0000000000000801","article-title":"Noninfectious vitritis after intravitreal injection of anti-VEGF agents: variations in rates and presentation by medication.","volume":"36","author":"Williams","year":"2016","journal-title":"Retina"},{"issue":"4","key":"eoi250016r29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/2474126420975303","article-title":"Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis.","volume":"5","author":"Witkin","year":"2021","journal-title":"J Vitreoretin Dis"},{"issue":"1","key":"eoi250016r30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review.","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"eoi250016r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2024.100742","article-title":"Immunogenicity and potential for intraocular inflammation of intravitreal anti-VEGF drugs.","volume":"100","author":"Kim","year":"2024","journal-title":"Curr Ther Res Clin Exp"},{"issue":"1","key":"eoi250016r32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1167\/iovs.13-11821","article-title":"Fc? receptor upregulation is associated with immune complex inflammation in the mouse retina and early age-related macular degeneration.","volume":"55","author":"Murinello","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"13","key":"eoi250016r33","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1038\/s41433-024-03079-0","article-title":"Intraocular inflammation with faricimab: insights from Manufacturer and User Facility Device Experience (MAUDE) database.","volume":"38","author":"Alkhawaldeh","year":"2024","journal-title":"Eye (Lond)"},{"issue":"7","key":"eoi250016r34","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.xphs.2019.02.002","article-title":"An assessment of the ability of submicron- and micron-size silicone oil droplets in dropped prefillable syringes to invoke early- and late-stage immune responses.","volume":"108","author":"Krayukhina","year":"2019","journal-title":"J Pharm Sci"},{"issue":"2","key":"eoi250016r35","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/bjophthalmol-2019-313823","article-title":"Release of silicone oil and the off-label use of syringes in ophthalmology.","volume":"104","author":"Melo","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"eoi250016r36","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling.","volume":"52","author":"Liu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2833392\/jamaophthalmology_binder_2025_oi_250016_1749757319.36474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:00:39Z","timestamp":1750417239000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2833392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.0969","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}